Skip to content

Schering-Plough SGP Cash & Equivalents

Cash & Equivalents at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$21.69B-43.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
Glaukos logo
GlaukosGKOS
$104.25M-8.8%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Bausch + Lomb logo
Bausch + LombBLCO
$279M+29.8%
HRO
HarrowHROW
$94.64M+41.8%

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's cash & equivalents?
Schering-Plough (SGP) reported cash & equivalents of $238.9M in Q1 2026.
How has Schering-Plough's cash & equivalents changed year-over-year?
Schering-Plough's cash & equivalents increased by 311.9% year-over-year, from $58M to $238.9M.
What is the long-term trend for Schering-Plough's cash & equivalents?
Over 2 years (2023 to 2025), Schering-Plough's cash & equivalents has grown at a 146.6% compound annual growth rate (CAGR), from $15.85M to $96.36M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.